hexamethylene bisacetamide has been researched along with Acute Promyelocytic Leukemia in 12 studies
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208
| Excerpt | Relevance | Reference |
|---|---|---|
| " The differentiation of acute promyelocytic leukemia cell line HL-60 cells could be induced by all trans-retinoic acid (ATRA) and hexamethylene bisacetamide (HMBA), but so far the mechanism was not demonstrated clearly." | 3.74 | Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. ( Bi, G; Dong, W; Jiang, G; Liu, J; Ren, X; Tang, T; Wen, P; Xie, C; Yang, W, 2007) |
| "All-trans retinoic acid (tRA)-induced differentiation in NB4 cells, a cell line derived from an acute promyelocytic leukemia patient with t(15;17) translocation, is markedly facilitated by sodium butyrate (NaB), a histone deacetylase inhibitor (HDACI), or by hexamethylene bisacetamide (HMBA), a non-HDACI tRA-differentiation inducer, as determined by nitroblue tetrazolium reduction." | 3.71 | Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. ( Jing, Y; Waxman, S; Xia, L, 2002) |
| "Treatment with hexamethylene bisacetamide (HMBA) combined with ATRA enhances ATRA-induced differentiation in ATRA-insensitive NB4-CI and arsenic-resistant NB4/As cells, and is associated with stabilization of PML-RARalpha protein and increased deltaPML-RARalpha formation." | 1.32 | The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells. ( Jing, Y; Lu, M; Waxman, S; Xia, L, 2003) |
| "Patients with acute promyelocytic leukemia (APL) associated with the t(15;17) translocation and fusion of the promyelocytic leukemia (PML) and retinoic acid receptor-alpha (RAR-alpha) genes achieve complete remission but not cure with all-trans retinoic acid (RA), NB4, a cell line derived from a patient with t(15;17) APL that undergoes granulocytic differentiation when treated with pharmacologic doses of RA, was used as a model for differentiation therapy of APL." | 1.29 | Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents. ( Chen, A; Hellinger, N; Licht, JD; Scher, W; Waxman, S; Wu, Y, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jing, Y | 2 |
| Xia, L | 2 |
| Waxman, S | 3 |
| Lu, M | 1 |
| Liu, J | 1 |
| Bi, G | 1 |
| Wen, P | 1 |
| Yang, W | 1 |
| Ren, X | 1 |
| Tang, T | 1 |
| Xie, C | 1 |
| Dong, W | 1 |
| Jiang, G | 1 |
| Kiefer, P | 1 |
| Bacher, M | 1 |
| Pflüger, KH | 1 |
| Chen, A | 1 |
| Licht, JD | 1 |
| Wu, Y | 1 |
| Hellinger, N | 1 |
| Scher, W | 1 |
| Hayashi, M | 1 |
| Albanell, J | 1 |
| Han, W | 1 |
| Mellado, B | 1 |
| Gunawardane, R | 1 |
| Scher, HI | 1 |
| Dmitrovsky, E | 1 |
| Moore, MA | 1 |
| Xi, ZF | 1 |
| Russell, M | 1 |
| Woodward, S | 1 |
| Thompson, F | 1 |
| Wagner, L | 1 |
| Taetle, R | 1 |
| Xie, D | 1 |
| Li, S | 1 |
| Ren, L | 1 |
| Taimi, M | 1 |
| Chen, ZX | 1 |
| Breitman, TR | 1 |
| Taylor, JL | 1 |
| Unverrich, D | 1 |
| O'Brien, WJ | 1 |
| Wilcox, KW | 1 |
| Kong, XB | 1 |
| Fanucchi, MP | 1 |
| Chou, TC | 1 |
1 review available for hexamethylene bisacetamide and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
[Experimental model for differentiation therapy of leukemia].
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Differentiation; DNA, Neoplasm; Flow Cytometry; Leu | 1993 |
11 other studies available for hexamethylene bisacetamide and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Topics: Acetamides; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Butyrates; | 2002 |
The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells.
Topics: Acetamides; Antineoplastic Agents; Arsenic; Blotting, Western; Cell Differentiation; Cell Line; Cycl | 2003 |
Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA.
Topics: Acetamides; Antineoplastic Agents; Cell Cycle; Cell Differentiation; Cell Proliferation; Cyclin E; C | 2007 |
Relationship of calcitonin mRNA expression to the differentiation state of HL 60 cells.
Topics: Acetamides; Calcitonin; Calcitonin Gene-Related Peptide; Cell Differentiation; Cell Division; Cholec | 1994 |
Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents.
Topics: Acetamides; Butyrates; Cell Differentiation; Cholecalciferol; Cytarabine; Drug Synergism; Humans; In | 1994 |
Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines.
Topics: Acetamides; Cell Differentiation; Embryonal Carcinoma Stem Cells; Humans; Leukemia, Promyelocytic, A | 1996 |
Expression of the Zn finger gene, EVI-1, in acute promyelocytic leukemia.
Topics: Acetamides; Alitretinoin; Cell Differentiation; DNA-Binding Proteins; Gene Expression Regulation, Le | 1997 |
Hydrophobic chromatography of the HL-60 cellular fraction co-binding with hexamethylene bisacetamide.
Topics: Acetamides; Antineoplastic Agents; Chromatography, High Pressure Liquid; HL-60 Cells; Humans; Leukem | 1997 |
Potentiation of retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bisacetamide.
Topics: Acetamides; Antineoplastic Agents; Butyrates; Butyric Acid; Cell Differentiation; Drug Synergism; Hu | 1998 |
Interferon coordinately inhibits the disruption of PML-positive ND10 and immediate-early gene expression by herpes simplex virus.
Topics: Acetamides; Animals; beta-Galactosidase; Chlorocebus aethiops; Drug Interactions; Gene Expression; G | 2000 |
Antagonistic interactions of hexamethylene bisacetamide in combination with 1-beta-D-arabinofuranosylcytosine, adriamycin and harringtonine on the growth and differentiation of HL-60 cells in vitro.
Topics: Acetamides; Alkaloids; Cell Differentiation; Cell Division; Cytarabine; Doxorubicin; Drug Interactio | 1988 |